Boundless Bio, Inc. (BOLD)
Market Cap | 191.04M |
Revenue (ttm) | n/a |
Net Income (ttm) | -49.43M |
Shares Out | 22.24M |
EPS (ttm) | -40.65 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 56,008 |
Open | 8.99 |
Previous Close | 9.10 |
Day's Range | 8.56 - 9.31 |
52-Week Range | 8.53 - 15.24 |
Beta | n/a |
Analysts | Strong Buy |
Price Target | 23.00 (+167.75%) |
Earnings Date | May 21, 2024 |
About BOLD
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for BOLD stock is "Strong Buy." The 12-month stock price forecast is $23.0, which is an increase of 167.75% from the latest price.
News
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with prev...
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with prev...
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with prev...
Boundless Bio Announces Pricing of Initial Public Offering
SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients wit...
Oncology biotech Boundless Bio files for a $100 million IPO
Boundless Bio, a Phase 1 biotech developing inhibitor therapies for oncogene amplified tumors, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Boundless Bio Eyes Nasdaq: Unveiling Cancer Therapy Innovation and IPO Ambitions
Boundless Bio, set to list on Nasdaq as BOLD, unveils its innovative cancer treatment strategy. A significant move reflecting investor confidence.
Boundless Bio IPO Registration Document (S-1)
Boundless Bio has filed to go public with an IPO on the NASDAQ.